Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/103/23/1738/7672994/djr386.pdf
Reference18 articles.
1. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study.
2. Cancer Trial Enrollment After State-Mandated Reimbursement
3. How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
4. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
5. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials;BMJ Oncology;2024-04
2. How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review;Trials;2023-11-06
3. Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit;Cancer Investigation;2021-12-27
4. Olaratumab-induced Biomarker Modulation in Sarcomas—Letter;Molecular Cancer Therapeutics;2021-10
5. Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics;European Urology Oncology;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3